Inherited thrombophilia (factor V Leiden, prothrombin G20210A, protein C/S/antithrombin deficiency) - ED approach
Coagulation / VTE · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Heritable hypercoagulable states increasing VTE risk. In the ED the priority is treating the acute thrombosis, NOT thrombophilia testing - results rarely change acute management, are unreliable during acute clot/on anticoagulation, and risk mislabelling. Know when (rarely) testing matters and counsel accordingly.
Red flags
- Recurrent VTE on adequate anticoagulation (reconsider APS, malignancy, compliance)
- Arterial + venous thrombosis together (think APS)
- Warfarin skin necrosis (protein C/S deficiency)
- Neonatal/childhood purpura fulminans (homozygous protein C/S deficiency)
- VTE at unusual site (cerebral/splanchnic) - consider PNH, MPN, APS
Assessment
Differential diagnosis
- Acquired thrombophilia: antiphospholipid syndrome, malignancy (Trousseau), nephrotic syndrome, PNH, HIT, pregnancy/oestrogen, MPN
- Provoked VTE (surgery, immobility, trauma)
- Unprovoked VTE needing malignancy consideration
Investigations
- Diagnose and treat the acute VTE first (Doppler/CTPA as appropriate) - see VTE pathway
- Do NOT send thrombophilia screen in the acute setting or while on anticoagulation (false results)
- Consider antiphospholipid screen (lupus anticoagulant, anticardiolipin, anti-beta2-GP1) where clinically relevant - affects management (warfarin over DOAC, duration)
- If testing is indicated, defer to outpatient: usually >=2 weeks after stopping anticoagulation (antithrombin/protein C/S functional assays unreliable on heparin/warfarin/during acute clot)
- Assess for acquired causes (malignancy, pregnancy, nephrotic syndrome) in unprovoked VTE
Management
- Treat acute thrombosis per standard VTE protocol (anticoagulation)
- Base duration of anticoagulation on whether VTE was provoked/unprovoked and bleeding risk - NOT on thrombophilia status in most cases
- Reserve heritable thrombophilia testing for selected cases where it changes management (e.g. some patients with strong family history, to guide relatives/pregnancy/contraception decisions) - usually a specialist outpatient decision
- ALWAYS test for antiphospholipid syndrome where arterial + venous clot, recurrent miscarriage, young stroke, or livedo/thrombocytopenia - it changes anticoagulant choice and duration
- Counsel on oestrogen-containing contraception/HRT avoidance and pregnancy thromboprophylaxis if known thrombophilia
- Refer to haematology/thrombosis clinic for counselling rather than testing in ED
Drugs & doses
Anticoagulation per VTE protocol - DOAC (apixaban/rivaroxaban) first-line for most VTE [verify local dose]
If antiphospholipid syndrome confirmed (esp. triple-positive/arterial): warfarin (target INR 2-3) preferred over DOAC [verify local dose]
LMWH for pregnancy-associated thrombophilia/thromboprophylaxis (DOACs/warfarin avoided in pregnancy) [verify local dose]
Antithrombin concentrate may be needed for antithrombin deficiency with heparin resistance [verify local dose]
Disposition
Treat acute VTE and arrange appropriate follow-up. Thrombophilia counselling/testing via outpatient haematology/thrombosis clinic, not ED.
Complications & pitfalls
- Recurrent VTE
- Pregnancy complications / loss
- Warfarin-induced skin necrosis (protein C/S deficiency when warfarin started without heparin cover)
- Mislabelling/anxiety and inappropriate lifelong anticoagulation from ill-timed testing
Exam pearls
- Thrombophilia testing is almost never an ED test - it is unreliable during acute clot/on anticoagulation and seldom changes acute care
- Antiphospholipid syndrome is the exception that matters acutely - it favours warfarin over DOAC and changes duration
- Duration of anticoagulation is driven by provoked vs unprovoked status and bleeding risk, not the thrombophilia result
- Start warfarin only under heparin cover in known/suspected protein C deficiency to avoid skin necrosis
- Unprovoked VTE: think occult malignancy and age-appropriate screening, not just heritable thrombophilia
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.